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INTRODUCTION
Since the ﬁrst umbilical cord blood (CB) transplantation
was performed by Gluckman et al. in 1988, more than
1500 patients worldwide have received related or unrelated
CB transplants for a variety of malignant and nonmalignant
diseases [1-16]. The majority of CB recipients have been
children with an average weight of 20 kg. The event-free
survival (EFS) rates reported thus far are comparable or
superior to results achieved following unrelated allogeneic
bone marrow transplantation [16]. Moreover, there are
many reports of what appears to be less graft-versus-host
disease (GVHD) than that associated with bone marrow
transplantation in children, despite the use of CB grafts with
substantially more donor-recipient HLA disparity than that
tolerated in recipients of marrow [4,5,9,10,13] or peripheral
blood progenitor cell (PBPC) [17-19] allografts.
The major disadvantage of CB is the low cell dose,
which results in slower time to engraftment and higher
rates of engraftment failure than occur with bone marrow
transplantation [20-24]. In published studies of CB trans-
plantation, the median times to an absolute neutrophil
count (ANC) of ≥0.5 × 109/L ranged from 22 to 34 days
[5,9,10,14,15]. Median times to a transfusion-independent
platelet count ≥20 × 109/L varied from 56 to more than
100 days, with engraftment failure rates of 12% to 18%.
However, the engraftment failure rate for the adult patients
(>18 years old and/or >45 kg) in those series was substan-
tially higher, ranging from 10% to 62%. These larger adult
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ABSTRACT
Umbilical cord blood (CB) from unrelated donors is increasingly used to restore hematopoiesis after myeloablative
therapy. CB transplants are associated with higher rates of delayed and failed engraftment than are bone marrow
transplants, particularly for adult patients. We studied the ex vivo expansion of CB in an attempt to improve time to
engraftment and reduce the graft failure rate in the recipients. In this feasibility study, 37 patients (25 adults,
12 children) with hematologic malignancies (n = 34) or breast cancer (n = 3) received high-dose therapy followed by
unrelated allogeneic CB transplantation. A fraction of each patient’s CB allograft was CD34-selected and cultured
ex vivo for 10 days prior to transplantation in defined media with stem cell factor, granulocyte colony-stimulating
factor, and megakaryocyte growth and differentiation factor. The remainder of the CB graft was infused without
further manipulation. Two sequential cohorts of patients were accrued to the study. The first cohort had 40% and
the second cohort had 60% of their CB graft expanded. Patients received a median of 0.99 × 107 total nucleated cells
(expanded plus unexpanded) per kilogram. The median time to engraftment of neutrophils was 28 days (range,
15-49 days) and of platelets was 106 days (range, 38-345 days). All evaluable patients who were followed for 28 days
or longer achieved engraftment of neutrophils. Grade III/IV acute GVHD was documented in 40% and extensive
chronic GVHD in 63% of patients. At a median follow-up of 30 months, 13 (35%) of 37 of patients survived. This
study demonstrates that the CD34 selection and ex vivo expansion of CB prior to transplantation of CB is feasible.
Additional accrual will be required to assess the clinical efficacy of expanded CB progenitors.
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patients might beneﬁt the most from the ex vivo expansion
of CB progenitor cells. In the majority of those studies,
there appears to be a threshold effect in the total nucleated
cell (TNC) dose of unmanipulated CB infused and time to
engraftment (patients who received doses above the median
for that particular study appeared to experience superior
engraftment to that of patients who received TNC doses
below the median). In a study reported by Gluckman et al.,
engraftment and survival were superior in patients who
received ≥3.7 × 107 TNC/kg [9]. This large a cell dose is not
generally available for patients weighing more than 45 kg.
For adult patients, it appears that recipients of ≥1.0 × 107
TNC/kg had more favorable engraftment than did recipi-
ents of lower cell doses [15]. The delays in engraftment and
engraftment failures in the studies referenced above could
be due to transplantation of a suboptimal number of pro-
genitor cells and/or to the more immature state of the CB
progenitors, requiring additional time for maturation [25].
We have previously demonstrated that human repopulating
CB CD34+ cells can give rise to cells that express myeloid
markers in the bone marrow within 1 week and in the
peripheral blood within 2 weeks following transplantation
into nonobese diabetic/severe combined immunodeﬁciency
disease (NOD/SCID) mice [26]. This result suggests that
maturation time may not be a factor in delayed granulocyte
recovery. Additionally, using the same model system, we
have found a dose response that correlates the magnitude of
human chimerism in mice with the number of input human
CB CD34+ cells transplanted [27]. Although not deﬁnitive,
together these data suggest that delayed engraftment in
patients may be due to a reduction in the number of appro-
priate CB repopulating cells. We postulated that the ex vivo
expansion of CB progenitors prior to transplantation could
potentially ameliorate inadequate hematopoietic recovery by
generating higher numbers of cells responsible for short-
term reconstitution. With that goal, we sought to identify
culture conditions that would produce expansion of com-
mitted myeloid and megakaryocytic CB progenitors without
compromising the long-term repopulating potential of
those and other cells in the graft. In preclinical studies,
CD34+ progenitors were isolated from CB and cultured for
10 days with stem cell factor (SCF), granulocyte colony-
stimulating factor (G-CSF), and megakaryocyte growth and
differentiation factor (MGDF) [28]. A median 100-fold
expansion of input myeloid and erythroid colony-forming
cells in culture and a 500-fold expansion of CD61+ mega-
karyocyte progenitors were consistently demonstrated. A
clinical trial using identical conditions to expand CD34+
PBPCs in the autologous transplant setting demonstrated an
improvement in time to neutrophil engraftment compared
to that of historical controls [29]. With these data as back-
ground, the clinical trial described below was designed and
executed, escalating the percentage of available CB cells to
be expanded as safety and efﬁcacy permitted.
PATIENTS AND METHODS
Patient Selection
Studies were approved by the Colorado Multiple Insti-
tutional Review Board (COMIRB) (protocols #96-154
[transplant] and #97-352 [CB expansion]), as well as the
Food and Drug Administration (BB-IND#7166); all patients
or their legal guardians gave written informed consent.
Patients with hematologic malignancies or breast cancer
lacking an HLA-matched sibling donor and willing to have
a portion of their CB graft expanded ex vivo prior to trans-
plantation were eligible for enrollment. Patients were
required to have normal vital organ function measured
within 30 days of study entry.
Between August 1997 and May 2000, 37 patients
(21 female and 16 male patients; 25 adults and 12 children)
were enrolled in this study. Follow-up for all patients in this
study was closed as of October 15, 2001, for purposes of this
report. The median age of the patients was 38 years (range,
1.3-60 years). As shown in Table 1, the median weight of the
patients was 61 kg (range, 9-116 kg). The diseases for which
the patients received transplants included acute myeloge-
nous leukemia (AML) (n = 10), acute lymphoblastic
leukemia (ALL) (n = 10), chronic myelogenous leukemia
(CML) (n = 3), chronic lymphocytic leukemia (CLL) (n = 3),
non-Hodgkin’s lymphoma (NHL) (n = 5), Hodgkin’s disease
(HD) (n = 3), and breast cancer (n = 3). This group of
patients had a uniformly poor prognosis and advanced dis-
ease according to the International Bone Marrow Trans-
plant Registry criteria [30]. Twenty-three of the 25 adult
patients had refractory disease at study entry. The HD,
NHL, and breast cancer patients had received a median of
3 (range, 1-5) prior standard-dose regimens. Nine of the
12 pediatric leukemic patients were beyond their ﬁrst com-
plete remission (CR1); the 3 patients in CR1 all had cytoge-
netic abnormalities (MLL+ [n = 2] or Ph+ [n = 1]).
Selection of CB Grafts
Patient and CB HLA typing was performed by serology
or low-resolution molecular testing for class I HLA-A and
HLA-B antigens and by high-resolution DNA typing for the
class II HLA-DRB1 alleles. Preferred CB units were those
that were matched at 6/6, followed by 5/6, and then 4/6 alle-
les. Nine patients received 6/6, 22 patients 5/6, and 6 patients
Table 1. Patient and Disease Characteristics*
Adults Children All
Characteristics (n = 25) (n = 12) (n = 37)
Patient-related
Age, median (range), y 40 (23-60) 9 (1.3-19) 38 (1.3-60)
Weight, median (range), kg 74 (54-116) 28 (9-84) 61 (9-116)
Male/Female 8/17 8/4 16/21
Diagnosis, n
AML 7 3 10
ALL 1 9 10
CML/CLL 6 0 6
NHL/HD/breast cancer 9 0 9
Status at transplantation, n
Stable disease (CML, CLL) 2 0 2
First CR 0 4† 4
Second CR 0 3 3
Third CR 0 3 3
Advanced (refractory/CML-AP) 23 2 25
*AP indicates accelerated phase.
†CR1 patients had monosomy 7 (n = 1), MLL+ (n = 2), and Ph+ (n = 1).
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4/6 HLA-matched units. For the 5/6 matches, 10 were mis-
matched at the A, 8 at the B, and 4 at the DR locus. For the
4/6 matches, 4 were mismatched at A and B and 2 at the B
and DR loci. There was no minimal CB cell dose require-
ment for this study, although attempts were made to obtain
CB which had ≥1 × 107 TNC/kg in the prethawed unit.
Twenty-ﬁve of the 37 patients had their CB units cryopre-
served in 1 fraction and were assigned to Stratum A; they
received CB units from the St. Louis University Cord Bank
(n = 9), New York Blood Center (n = 7), Australian Cord
Bank (n = 2), University of Massachusetts (n = 3), University
of Dusseldorf (n = 1), and banks in Malaga, Spain (n = 2) and
Bergin, New Jersey (n = 1). Twelve patients had their CB
units cryopreserved in 2 fractions and were assigned to Stra-
tum B; their units came from the CB banks at the University
of Colorado (n = 11) in 40% and 60% fractions and at the
University of Dusseldorf (n = 1) in two 50% fractions.
Treatment Schema
For a back-up hematopoietic graft, either an autologous
marrow or PBPC fraction was harvested and cryopreserved
or a second alternative donor (CB or family member) was
identified. As shown in Figure 1A, Stratum A patients
(whose CB grafts were cryopreserved in a single fraction)
received the high-dose therapy regimens described below on
days –8 through –2. On day 0, the entire CB unit was
thawed; 40% (Cohort 1) or 60% (Cohort 2) of the CB cells
were CD34-selected and placed into expansion culture, as
described below, while the remaining 60% (Cohort 1) or
40% (Cohort 2) of the cells were infused immediately with-
out further manipulation. On day +10, the expanded CB
cells were washed and infused. As shown in Figure 1B, Stra-
tum B patients (whose CB grafts were cryopreserved in
2 fractions) had 40% (cohort 1) or 60% (cohort 2) of their
CB grafts thawed, CD34-selected, and placed into expansion
culture on day –10, prior to high-dose therapy administra-
tion. On days –8 through –2, the patients received high-
dose therapy. The expanded cells that had been in culture
for 10 days were harvested on day 0, washed, and infused.
Approximately 3 hours later, the remaining fraction of the
unmanipulated CB cell graft was thawed and immediately
infused. Following the initial CB infusion on day 0, all
patients received 10 µg/kg per day of G-CSF systemically
until the ANC was ≥5.0 × 09/L (adult patients) or ≥2.5 ×
109/L (pediatric patients). The patients were assigned to the
strata and cohorts described in Table 2.
Preparative Regimens
One of the 3 high-dose regimens speciﬁed in the proto-
col was administered, based on patient age, underlying dis-
ease, and prior therapy. Twenty adult patients with hemato-
logic malignancies received fractionated total body
irradiation (TBI) of 1200 cGy total, delivered in 200-cGy
fractions twice daily on days –8, –7, and –6, plus melphalan
46.5 mg/m2 (n = 10) or 33.3 mg/m2 (n = 10) administered
daily for 3 days on days –5, –4, and –3. The melphalan dose
was reduced from a total of 140 mg/m2 to 100 mg/m2
because of excessive regimen-related toxicity midway
through the trial. The breast cancer patients (n = 3) and pre-
viously irradiated lymphoma patients (n = 2) received oral
Table 2. Cohort Escalation Schema*
Stratum Cohort % CB Expanded n (Adults + Children)
A 1 40 14 (10 + 4)
A 2 60 11 (6 + 5)
B 1 40 8† (6 + 2) 
B 2 60 4 (3 + 1)
Total 37 (25 + 12)
*Cord unit cryopreserved in 1 (stratum A) or 2 (stratum B) fractions.
†One patient had the cord unit cryopreserved in two 50% fractions
and thus received 50% rather than 40% expanded CB.
Figure 1. A, Stratum A: cord unit in 1 fraction. Patients received high-dose therapy on days –8 to –2. On day 0, the entire CB unit was thawed;
40% (cohort 1) or 60% (cohort 2) of the CB cells were CD34-selected and placed into expansion culture, while the remaining 60% (cohort 1) or
40% (cohort 2) of the cells were infused immediately without further manipulation. On day +10, the expanded CB cells were washed and infused.
Systemic G-CSF was initiated on day 0 and continued until an ANC of 2.5 × 109/L (children) or 5 × 109/L (adults) was reached. B, Stratum B: cord
unit in 2 fractions. Patients had 40% (cohort 1) or 60% (cohort 2) of their CB grafts thawed, CD34-selected, and placed into expansion culture on
day –10. On days –8 through –2, the patients received high-dose therapy. The expanded CB cells were harvested on day 0, washed, and infused.
Approximately 3 hours later, the remaining fraction of the unmanipulated CB cell graft was thawed and immediately infused.
A B
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busulfan every 6 hours for a total of 16 doses, adjusted to
provide a cumulative area under the curve exposure over
4 days of 16,000, on days –8, –7, –6, and –5, in combination
with melphalan 46.5 mg/m2 on days –4, –3, and –2. The
12 pediatric patients received 1200 cGy TBI in 200-cGy
fractions twice daily on days –8, –7, –6, plus cytosine arabi-
noside 2000 to 2500 mg/m2 every 12 hours for a total of
6 doses and cyclophosphamide 45 mg/kg daily for 2 doses
on days –3 and–2. All patients received horse antithymocyte
globulin (ATG) 30 mg/kg daily on days –5, –4, and –3.
GVHD Prophylaxis Regimens
Cyclosporine and prednisone were administered to all
patients for GVHD prophylaxis. Cyclosporine administra-
tion began on day –1; the dose was adjusted to maintain a
blood cyclosporine level of 350 to 450 ng/mL (adults) or
150 to 250 ng/mL (children). If no GVHD was present on
day 100, a cyclosporine taper was initiated and completed
over 3 months. The ﬁrst 8 patients received very high-dose
methylprednisolone, 10 mg/kg on day –4, 5 mg/kg on day
–3, and 2 mg/kg per day on day –2 through day 2, followed
by a taper at 5% of dose per week. A high incidence of
infectious complications prompted a reduction in the steroid
dose. The subsequent 29 patients received moderate-dose
steroids. The adults received methylprednisolone 0.4 mg/kg
per day from day 0 through day 4, followed by 1 mg/kg per
day from days 5 through 20, with a 5% per dose per week
taper initiated on day 21 if no GVHD was documented.
The pediatric patients received methylprednisolone 5 mg/kg
per day from day –5 through day –2, 2 mg/kg per day from
day –1 through day 1, and then 2 mg/kg every other day
alternating with 1 mg/kg from day 2 through day 19, fol-
lowed by a taper at 5% of dose per week.
GVHD Assessment
During the ﬁrst 100 days, patients were evaluated daily
for acute GVHD, which was graded according to standard
criteria [31]. After day 100, patients were evaluated for
chronic GVHD, which was also graded according to stan-
dard criteria, at each visit [32].
CB Manipulations
CB Thawing Procedure. Frozen CB fractions were thawed
using the procedure developed by Rubinstein et al. [33].
Brieﬂy, the volume of the CB unit was doubled slowly with a
1:1 suspension of 10% dextran 40 (Braun Medical, Irvine,
CA) and 5% human serum albumin (HSA) (American Red
Cross, Washington, DC); an additional 50 mL of 10% dex-
tran 40 was then added for a 5-minute incubation, followed
by centrifugation at 464g for 10 minutes. The supernatant
was expressed and another 50 mL of the 10% dextran
40/5% HSA suspension was added. Prior to infusion or
CD34-selection, samples were taken for enumeration of
nucleated cells using the Sysmex XE-2100 hematology ana-
lyzer, enumeration of CD34+ cells using the ﬂow cytometric
procedure described below, viability assessment using trypan
blue exclusion dye, and routine bacterial and fungal micro-
biologic cultures.
CB CD34-Selection Procedure. The fraction of CB cells to
be expanded was CD34-selected using the Isolex 300-i
device (Nexell, Irvine, CA). The anti-CD34 monoclonal
antibody, PR34+ stem cell releasing agent, and magnetic
beads were prepared according to manufacturer’s instruc-
tions. A buffered suspension was made by adding 120 mL of
25% HSA and 360 mL of sodium citrate (Baxter Fenwal,
Deerfield, IL) to 3 L of phosphate-buffered saline (PBS)
(Nexell). Pulmozyme/MgCl2 was prepared by adding
0.6 mL 500mM MgCl2 to 15 mL Pulmozyme (Genentech,
South San Francisco, CA) containing 1500 units of recom-
binant dornase alpha. CB cells were incubated with 10 mL
of 5% immune globulin (Baxter Hyland, Glendale, CO) for
15 minutes at room temperature and ﬁltered prior to being
loaded on the selection device. CB cells were CD34-selected
following the manufacturer’s instructions, except that the
Pulmozyme/MgCl2 and magnetic beads were added to the
incubation chamber at the “Transfer Cells to Chamber” step
following the “Antibody Wash” procedure. The isolated
CD34+ fraction was centrifuged in 50 mL sterile conical
tubes at 617g for 10 minutes. Supernatant was removed and
the cells were resuspended in deﬁned media (Amgen, Thou-
sand Oaks, CA) Samples of the washed CD34+ CB cells
were then taken for enumeration of nucleated cells and
CD34+ cells, viability assessment, and microbiologic cultures
prior to inoculation into expansion culture. The CD34–
(unselected) fraction was cryopreserved in 2 Cryocyte freez-
ing bags (Nexell) for possible future use.
CB Expansion Procedure. The CD34+ CB cells were
placed in a 1 L VueLife Teﬂon ﬂuorinated ethylene propy-
lene bag (American Fluoroseal Corporation, Gaithersburg,
MD) with 800 mL of deﬁned media (Amgen) and 100 ng/mL
each of SCF, G-CSF, and MGDF (Amgen). The cells were
cultured for 10 days in a 5% CO2 incubator at 37°C without
further manipulation or refeeding. On day 10 of culture, the
expanded CB cells were transferred into 50-mL sterile
conical tubes, centrifuged at 617g for 5 minutes, and then
washed twice with the PBS/sodium citrate/HSA buffer
described above. Samples of the expanded CD34+ CB cells
were taken for enumeration of nucleated cells and CD34+
cells, viability assessment, and microbiologic cultures prior
to infusion.
Flow Cytometric Analysis. Small aliquots (1-5 × 105 cells)
from the unmanipulated, CD34-selected, and expanded CB
fractions were stained with a phycoerythrin-conjugated anti-
CD34 antibody (Coulter, Hialeah, FL). Flow cytometric
analysis for CD34 expression was performed with a Coulter
Epics flow cytometer using the International Society for
Hematotherapy and Graft Engineering (ISHAGE) proce-
dure [34]; 100,000 events were counted for the preselected
and expanded fractions; 20,000 events were counted for the
CD34-selected fractions.
Statistical Analysis
Patients were stratiﬁed according to whether their CB
unit was cryopreserved in 1 fraction (stratum A) or 2 frac-
tions (stratum B). Exploratory analyses were performed to
compare the 2 strata with respect to neutrophil and platelet
engraftment, and then the strata were combined for the ﬁnal
analyses. Patients who were followed for a minimum of 28 days
without evidence of progressive disease in the marrow were
evaluated for neutrophil engraftment, the primary endpoint
of this study. Time of neutrophil engraftment was deﬁned as
the ﬁrst of 3 consecutive days with a sustained ANC ≥0.5 ×
E. J. Shpall et al.
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109/L. Time of platelet engraftment was deﬁned as the ﬁrst
of 3 consecutive days with a platelet count ≥20 × 109/L,
without platelet transfusion support in the preceding 7 days.
The proportion of patients who achieved engraftment at
various time points was based on cumulative incidence, with
death (with or without relapse) as a competing risk [35].
Trend tests of cumulative incidence across CD34 and TNC
dose categories were based on the methods of Fine and
Gray [36]. EFS was estimated by the Kaplan-Meier method,
censoring those patients who died early on the day of death
[37]. The log-rank test was used for comparing EFS rates
between adult and pediatric patients. The Fisher exact test
was used to test the difference in the rate of GVHD
between pediatric and adult patients. The Fisher exact test
and the Mantel-Haenszel (linear-by-linear association) chi-
square tests were applied to examine the association between
HLA match and the development of GVHD. All statistical
analyses were carried out with SAS software (Version 8.1,
SAS Institute, Cary, NC).
RESULTS
CB Expansion Data
The pre-thaw TNC doses were based on the nucleated
cell counts reported by the CB bank from which the CB
unit was obtained. The post-thaw TNC and CD34+ cell
doses were determined in the University of Colorado Stem
Cell Laboratory using the procedures described above. As
summarized in Table 3, the median number of TNC/kg in
the pre-thawed CB units was 1.60 × 107 TNC/kg (1.43 ×
107 TNC/kg for the adult and 4.20 × 107 TNC/kg for the
pediatric patients). Following thawing, a median 74% cell
recovery resulted in 1.19 × 107 TNC/kg in the post-thaw
CB fractions (0.95 × 107 TNC/kg for the adult and 3.29 ×
107 TNC/kg for the pediatric patients). Following the
expansion procedure, the median TNC expansion was 56-
fold higher and the CD34+ cell expansion was 4.0-fold
higher than the preculture values in the CD34-selected frac-
tions. A median of 0.99 × 107 total (expanded plus unex-
panded) TNC/kg was infused (0.79 × 107 TNC/kg for the
adult and 2.14 × 107 TNC/kg for the pediatric patients).
Table 4 shows that a median of 7.35 × 104 CD34+ cells/kg
were contained in the thawed CB units prior to further
manipulation (6.55 × 104 CD34+ cells/kg for the adult and
16.1 × 104 CD34+ cells/kg for the pediatric patients). Fol-
lowing CD34 selection and expansion, a total (expanded plus
unexpanded) of 10.4 × 104 CD34+ cells/kg was infused (8.9 ×
104 CD34+ cells/kg for the adult and 21.1 × 104 CD34+
cells/kg for the pediatric patients).
Infusion and Engraftment Data
There was no signiﬁcant acute toxicity associated with
infusion of the expanded or the unmanipulated CB cells. Four
patients died of disseminated fungal infections (1 Aspergillus, 1
Chaetonium, 2 Candida) before day 28 on days 14, 18, 24, and
27, prior to engraftment of their neutrophils. Three addi-
tional patients developed extensive relapse in the marrow and
died, pancytopenic, on days 41, 51, and 78. None of the
remaining 30 patients experienced neutrophil engraftment
failure. The median time to an ANC ≥0.5 × 109/L was 28 days
(range, 15-49 days) (35 days for adult and 25 days for pedi-
atric patients). The median time to an unsupported platelet
count ≥20 × 109/L was 106 days (range, 38-345 days)
(261 days for adult and 65 days for pediatric patients). As
shown in Table 5, there were no significant differences in
times to neutrophil or platelet engraftment between Stratum A
(expanded CB cells infused on day 10) and Stratum B
(expanded CB cells infused on day 0), nor between Cohort 1
(40% CB fraction expanded) and Cohort 2 (60% CB fraction
expanded). There was no signiﬁcant correlation between time
to neutrophil engraftment and the number of TNC/kg in the
pre-thaw or the post-thaw CB fractions. As shown in Figure
2, for the infused CB fraction (P = .27), a delay in engraft-
ment is evident for the lowest TNC dose category, but some
delays also occurred in the higher dose categories. As shown
in Figure 3, there does appear to be an association between
the number of CD34+ cells/kg (expanded plus unexpanded)
infused and time to neutrophil engraftment. Patients who
received ≥5 × 104 CD34+ cells/kg had a more rapid time to
neutrophil engraftment compared to recipients of lower
CD34+ cell doses, but because of the small number of
Table 3. TNC Data
Parameter Median Range
TNC fold expansion* 56 1.03-278
Pre-thaw TNC/kg, ×107†
All patients 1.60 0.67-9.44
Adults 1.43 0.67-6.70
Children 4.20 0.98-9.44
Post-thaw TNC/kg, ×107‡
All patients 1.19 0.56-8.86
Adults 0.95 0.56-2.0
Children 3.29 1.14-8.86
Infused TNC/kg, ×107
All patients 0.99 0.28-8.50
Adults 0.79 0.28-2.35
Children 2.14 0.75-8.50
*Fold expansion = TNC post expansion/TNC in CD34+ fraction.
†Pre-thaw based on count reported by the cord bank supplying the
cord unit.
‡Post-thaw based on University of Colorado Stem Cell Laboratory
assays.
Table 4. CD34+ Cell Data
Parameter Median Range
CD34+ cell fold expansion* 4.0 0.1-20.0
Post-thaw CD34+ cells/kg, ×104†
All patients 7.35 0.55-109.0
Adults 6.55 0.55-19.7
Children 16.1 4.51-109.0
Infused CD34+ cells/kg, ×104
All patients 10.4 0.97-311.0
Adults 8.9 0.97-51.0
Children 21.1 1.99-311.0
*Fold expansion = CD34+ cells postexpansion/CD34+ cells in
CD34+ fraction.
†Post-thaw based on University of Colorado Stem Cell Laboratory
assay.
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patients the differences were not statistically signiﬁcant (P =
.095). There also appeared to be a correlation between TNC
dose and time to platelet engraftment. However, more than
60% of the patients had prolonged thrombocytopenia associ-
ated with chronic GVHD, and thus the independent validity
of this correlation could not be conﬁrmed. At the time of this
report, there were no cases of late graft failure or loss of
donor chimerism, with a median follow-up of 30 months in
surviving patients.
Graft versus Host Disease
Acute GVHD was documented in 20 (66.7%) of the
30 evaluable patients followed 28 days or longer; 8 (26.7%)
of the 30 had grade 2, and 12 (40%) of the 30 developed
grades 3 to 4 GVHD. One (3%) of the grade 4 patients died
from complications of acute GVHD on day 87. Chronic
GVHD was documented in 14 (74%) of the 19 evaluable
patients followed 100 days or longer. Two (11%) of the
19 patients had chronic GVHD limited to the skin, whereas
12 patients (64%) developed extensive chronic GVHD
involving the gastrointestinal tract, liver, and/or lung. One
patient (5%) died on day 141 of chronic GVHD of his lung
and liver. Both patients who died of GVHD were adults.
Table 6 compares the rates of acute and chronic GVHD,
respectively, for the adult versus pediatric patients. The
proportion of patients with GVHD was higher in the adults
(80% acute, 90% chronic) than in the children (40% acute,
56% chronic), but because of the small number of patients
the differences were not statistically signiﬁcant (acute, P =
.2134; chronic, P = .1409). There was no difference in the
time of onset of acute GVHD in patients who received the
expanded cells on day 0 (Stratum B) versus those who
received them on day 10 (Stratum A). There was also no
association between the degree of HLA matching and the
development of acute or chronic GVHD. The small num-
bers of patients enrolled in this trial preclude deﬁnitive con-
clusions about these issues.
Current Status
At the time of this report, 12 (32%) of the 37 patients,
including 5 of the 25 adults (25%) and 7 of the 12 children
(58%), remained alive. All of the surviving pediatric
patients and 4 of 5 surviving adults remained free of dis-
ease. Eleven of the 37 patients (30%) died as a result of
progressive disease; 2 of these 11 were pediatric patients
with AML refractory to induction and ALL in second com-
plete remission at the time of transplant, respectively; 9 of
11 relapses occurred in adult patients, all of whom had
refractory progressive disease at the time of transplant, with
AML (n = 4), HD (n = 2), NHL (n = 1), ALL (n = 1), and
breast cancer (n = 1). Fourteen of the 37 patients (38%)
experienced fatal non–relapse-related complications. The
causes of nonrelapse mortality were GVHD (n = 2), failure
to thrive (n = 1; patient died bedridden, anorectic, refusing
all medication and nutritional support, with no clinical evi-
dence of GVHD, infection, or relapse), central nervous
system bleeding (n = 3), primary central nervous system
toxicity in a patient who had received prior brain irradia-
tion (n = 1), pulmonary toxicity (n = 2), resistant dissemi-
nated herpes (n = 1), and fungal infections (n = 4).
DISCUSSION
Over the past decade, CB has been used with increasing
frequency as a source of allogeneic hematopoietic support for
patients lacking HLA-matched sibling donors. The logistical
Table 5. Time to ANC >0.5 × 109/L and Platelet Count >20 × 109/L*
Stratum A (Day 10) Stratum B (Day 0) Cohort 1 (40%) Cohort 2 (60%)
Median days to ANC >500 26 31 26 30
Range 15-49 15-41 15-45 22-49
P = .8613 P = .3192
Median days to platelets >20,000 126 73 91 126
Range 38-345 56-165 38-345 43-148
P = .6905 P = .9161
*There were no significant differences in times to neutrophil or platelet engraftment between Stratum A (expanded CB cells infused on day
10) and Stratum B (expanded CB cells infused on day 0), or between Cohort 1 (40% CB fraction expanded) and Cohort 2 (60% CB fraction
expanded).
Figure 2. Neutrophil engraftment by TNC infused per kilogram.
The kinetics of neutrophil engraftment posttransplantation are plotted
against the number of TNC infused per kilogram patient weight
(includes the combined expanded plus unexpanded CB fractions).
Time to neutrophil engraftment appeared to be longer in the group of
patients with the number of TNC/kg in the infused CB fraction <1 ×
107, but some delays were also seen in those patients infused with 1 to
2 × 107 or >2 × 107 TNC/kg (Fine and Gray trend test: χ2 = 1.24 with
1 df, P = .27).
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ease and rapidity of procuring CB units that are HLA typed,
cryopreserved, and ready to transplant are major advantages
over procurement of cells from living unrelated donors, partic-
ularly for patients with rapidly progressive malignancies. The
common CB bank practice of targeting CB collections from
minority donors is making it progressively easier to ﬁnd appro-
priately matched CB units for minority patients, who are
poorly represented in national and international bone marrow
donor registries [38]. Finally, it has become clear that less strin-
gent HLA matching is required for CB compared to unrelated
marrow or PBPC transplants [16,39]. The less stringent
matching allows many patients who do not have a suitably
HLA-matched bone marrow or PBPC donor to receive high-
dose therapy and allogeneic CB transplants. Complete remis-
sions and long-term survival can be obtained for such patients
who would otherwise certainly succumb to their underlying
disease. The major disadvantage of CB compared to bone mar-
row is the lower available cell dose, with the resultant delays in
engraftment and higher rates of graft failure discussed above.
The CB expansion strategy described in the report was
designed to improve the engraftment results of unmanipulated
CB transplants.
Our preliminary results demonstrated that it is feasible
and safe to administer expanded CB progenitors to patients
with high-risk malignancies following myeloablative ther-
apy. At a median follow-up of 30 months, there were no
cases of late graft failure. Moreover, >95% long-term donor
chimerism was documented in all patients, demonstrating
that sufficient stem cells were in the CB graft to produce
long-term engraftment. In this study, we defined patients
with graft failure to be patients followed for 28 days or
longer who did not have engraftment and did not have
extensive relapse in the marrow. We cannot exclude the pos-
sibility that the 4 patients in the study who died early might
have experienced engraftment failure had they lived
≥28 days. Additional accrual is necessary to assess the impact
of the expanded CB cells on times to neutrophil and platelet
engraftment and the true engraftment failure rate.
In the current study, following the CD34-selection and
expansion procedures, the number of nucleated cells in the
CB graft was slightly lower and the number of CD34+ cells
slightly higher than the numbers in the thawed unit before
the CD34-selection and expansion procedures were per-
formed. We believe that the quality, not the quantity, of CB
cells is important for improving engraftment kinetics. A
signiﬁcant number of the nucleated cells in a CB graft, or any
hematopoietic graft, are not able to proliferate and are thus
incapable of producing the requisite granulocytes needed for
rapid neutrophil engraftment. The goal of our expansion
strategy is to enrich for a cell population that is highly prolif-
erative and capable of generating rapidly engrafting cells.
Thus, if there is an effect of the expansion, allowing smaller
cell doses to engraft or reducing the incidence of graft failure,
it is likely due to CD34-selection and culture-induced alter-
ations in the engraftment potential of the CB rather than an
absolute increase in the total numbers of nucleated or CD34+
cells. Ultimately, we believe that expansion will decrease the
risk of delayed myelosuppression and engraftment failure,
even though the nucleated cell dose may be lower than that of
an unmanipulated graft. Of course, the number of patients
accrued to date in this study is too small for any deﬁnitive
conclusions about efﬁcacy to be made.
The CD34-selection procedure using the Isolex device
yields only 30% to 45% of the initial thawed CD34+ cells.
Clearly, procedures that limit the TNC and CD34+ cell
losses incurred with CD34 selection would result in higher
numbers of cells available for expansion. Studies evaluating
alternative CD34-selection devices [40] and expansion pro-
cedures that do not require CD34 selection [41] are in
progress and will be evaluated clinically in the future, in an
attempt to improve the magnitude and efficacy of CB
expansion.
In previous reports of unmanipulated CB transplantation,
there appeared to be a correlation or threshold effect between
neutrophil engraftment and the nucleated cell dose [5,9,10,15].
Figure 3. Neutrophil engraftment by CD34+ cells infused per kilo-
gram. The kinetics of neutrophil engraftment posttransplant are plot-
ted against the total number of CD34+ cells infused per kilogram
patient weight (includes the combined expanded plus unexpanded CB
fractions). There is an association between the number of CD34+ cells
per kilogram (expanded plus unexpanded) infused and time to neu-
trophil engraftment. Patients who received ≥5 × 104 CD34+ cells/kg
appeared to have a more rapid time to neutrophil engraftment com-
pared to that of recipients of lower CD34+ cell doses (Fine and Gray
trend test: χ2 = 2.78 with 1 df, P = .095).
Table 6. GVHD in Adult versus Pediatric Patients*
Acute GVHD Chronic GVHD
Summary Summary
Adults Children Total Adults Children Total
Evaluable, n 20 10 30 10 9 19
GVHD, n 16/20 4/10 20/30 9/10 5/9 14/19
GVHD 80% 40% 67% 90% 56% 74%
P .2134 .1409
*The Fisher exact test was used to test the difference in propor-
tion of GVHD between adult patients (16/20 with acute, 9/10 with
chronic) and pediatric patients (4/10 with acute, 5/9 with chronic).
We note that the proportion of GVHD was higher in adults (80%
acute, 90% chronic) than in pediatric patients (40% acute, 56%
chronic). However, the difference was not significant (P = .2134
acute, P = .1409 chronic).
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These studies based their analyses on the number of cells in the
CB unit before thawing. In our study, there appears to be no cor-
relation or threshold effect between neutrophil engraftment and
TNC/kg in the CB unit, either before or after thawing. The lat-
ter analyses included the TNC/kg in the unmanipulated frac-
tion, the expanded fraction, and the combination of both. The
small numbers of patients preclude making a deﬁnitive conclu-
sion about the lack of correlation. There does appear to be an
association, however, between the CD34+ cell dose in the thawed
CB fractions (unmanipulated, expanded, and both) and time to
neutrophil engraftment. The patients in Stratum B who received
their expanded cells on day 0 had times to engraftment similar to
those of patients in stratum A who received their expanded cells
on day 10. Similarly, patients accrued to Cohort 2 (60% fraction
expanded) had engraftment times similar to those of Cohort 1
patients (40% expanded). The small size of these subgroups lim-
ited the power to make deﬁnitive comparisons. Nevertheless, we
postulated that an expansion product with more mature commit-
ted progenitors and mature cells would be needed to facilitate
engraftment to a clinically relevant degree. In a PBPC expansion
study conducted at our center during the same time period,
patients had their autologous G-CSF–mobilized PBPC fractions
expanded for 10 days with the same media and growth factors
used for the CB expansion study [29]. The expanded PBPC
products contained many more mature-appearing cells of neu-
trophil lineage, and those patients achieved engraftment more
rapidly than did historical controls (within 4-8 days). Based on
those data, we have modiﬁed our 10-day culture method to gen-
erate expanded CB that looked morphologically like the
expanded PBPC fractions. In preclinical studies, a modiﬁed 14-
day method resulted in a median 460-fold expansion of TNCs,
compared to a median 98-fold TNC expansion using the stan-
dard 1-step 10-day culture conditions [42]. The morphology of
the day 14 (2-step) expanded CB cells looked very similar to our
cultures of expanded PBPC and included a signiﬁcantly higher
proportion of bands and mature neutrophils (67%) compared to
the proportion in the day 10 (1-step) expansion (10%). There-
fore, we have now begun accruing patients to Cohort 3 of this
study, which uses the new 14-day expansion method, and that
data will be forthcoming.
The GVHD rate in this study appears to be higher than
that reported by others, particularly for the adult patients
[4,5,9,15]. The CD34-selected and expanded CB fractions
had no detectable T-cells on ﬂow cytometric analysis. Pre-
liminary morphologic analysis of the expanded products
demonstrated the presence of mature dendritic-like cells,
which could be contributing to the development of GVHD.
Comprehensive studies to identify the phenotypic and
functional characteristics of those cells are in progress, and
that data will be forthcoming. The GVHD prophylaxis reg-
imen and schedule employed in this study may have con-
tributed to the high rate of GVHD. A day –5 to –3 sched-
ule of ATG was used in the current study, compared to days
–3 to –1 in other reports in which less GVHD was docu-
mented [4,5,9,15]. We began to taper the cyclosporine at
day 100 in the majority of patients, if there was no evidence
of GVHD. In initial CB transplantation studies where
lower GVHD rates were reported, tapering of cyclosporine
was not initiated until 6 to 9 months posttransplantation,
even in the absence of GVHD [4,5,9,15]. Our ongoing CB
transplantation trials will employ the days –3 to –1 ATG
schedule and delay the tapering of cyclosporine until at
least 6 months posttransplantation. Once the optimal
expansion procedure and time to engraftment are deﬁned,
adding methotrexate will be considered to reduce the inci-
dence and severity of GVHD, while monitoring for any
engraftment delays.
Although the 20% survival rate for the adult patients is
low, they were heavily pretreated, with the vast majority
(23 of 25) having had progressive refractory disease at study
entry. In contrast, the 58% EFS rate for the pediatric
patients is comparable to our results in matched sibling
transplantations and other published pediatric CB transplan-
tation reports [4-6,8-10,12,13,15]. Four patients (3 adults,
1 child) died of disseminated fungal infections on days 14,
18, 24, and 27. These patients all had either evidence of fun-
gal colonization immediately pretransplantation (n = 3) or a
previously documented fungal infection (n = 1). The reduc-
tion in the methylprednisolone and melphalan doses should
result in lower infection and regimen-related toxicity rates,
respectively, as accrual to the study continues. Once optimal
engraftment is achieved, studying CB expansion in adult
patients with a better prognosis would also be expected to
produce improved outcome. Shortening the time to neu-
trophil engraftment with improved CB expansion strategies
should reduce the infectious and organ-toxic complication
rates in the future.
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